Fluvoxamine
Intervention1 paper3 findingsPubChem 5324346ChEBI 5138
- Human trial1
Outcomes
3Adverse event incidence
downin humans1High certainty
1 study
Adverse event incidence
downin humans1High certainty
Fluvoxamine decreases adverse event incidence in humans (24.0% versus 45.1% with metformin 750 mg BID, 42.5% with metformin 500 mg BID, and 35.5% with placebo).
Human triallong COVID-associated fatigue; compared with metformin and placebo100 mg twice daily
Fluvoxamine may ease fatigue in adults with long COVID · Annals of internal medicine · 6 Oct 2026
Quality of life
upin humans1High certainty
1 study
Quality of life
upin humans1High certainty
Fluvoxamine improves quality of life in humans.
Human triallong COVID-associated fatigue100 mg twice daily
Fluvoxamine may ease fatigue in adults with long COVID · Annals of internal medicine · 6 Oct 2026
Fatigue Severity Scale score
downin humans1High certainty
1 study
Fatigue Severity Scale score
downin humans1High certainty
Fluvoxamine decreases Fatigue Severity Scale score in humans (Mean difference versus placebo: -0.43 at day 60 and -0.58 at day 90; 99% posterior probability of superiority at both times).
Human triallong COVID-associated fatigue; compared with placebo100 mg twice daily60 days of treatment; assessment at day 90
Fluvoxamine may ease fatigue in adults with long COVID · Annals of internal medicine · 6 Oct 2026
Latest
1Fluvoxamine may ease fatigue in adults with long COVID
Mean Fatigue Severity Scale scores were 0.43 points lower than placebo at day 60 and 0.58 points lower at day 90.Mean Fatigue Severity Scale scores were 0.43 points lower than placebo at day 60 and 0.58 points lower at day 90.